Menu

DISCOVER THE EFFICACY OF THE FIRST AND ONLY IL-17A + IL-17F INHIBITOR1-5

BIMZELX DELIVERS
FAST, COMPLETE, AND
MAINTAINED CLEARANCE1-5

BIMZELX provided clearance from the very first dose that lasted through 3 years.*

Explore Efficacy

OLE LIMITATIONS: The open-label extension has limitations with a lack of comparator and the potential enrichment of the patient population.

*From the very first dose as measured at Week 4; results were not immediate.

SUPERIOR TO
THE COMPETITION

In head-to-head studies against COSENTYX®, HUMIRA®, and STELARA®, BIMZELX delivered superior results.3-5

See head-to-head data

BIMZELX demonstrated superior PASI 90 or PASI 100 clearance at Week 16 and PASI 75 clearance at Week 4 compared to comparator biologics.

PASI=Psoriasis Area and Severity Index.

TRANSFORMATIVE
SKIN CLEARANCE6

Image of an arm from wrist to shoulder. A portion of the arm is slightly pink showing transformative skin clearance. The words “Week 4: PASI 75” appear in the top left corner of the image.


EXPLORE PATIENT
BEFORE & AFTER

Actual patient from the BE VIVID clinical trial who received a dose of 320 mg Q4W to Week 52. The recommended dose for BIMZELX is 320 mg Q4W for 16 weeks, then Q8W thereafter. For patients ≥120 kg, consider a dosage of 320 mg every 4 weeks after Week 16.

PASI=Psoriasis Area and Severity Index; Q4W=every 4 weeks; Q8W=every 8 weeks.

COMPLETE CLEARANCE FOR
BIO-EXPERIENCED PATIENTS7

Patients who switched to BIMZELX experienced
rapid and complete skin clearance, even after transitioning from another IL-17.

VIEW THE RESULTS

IL=interleukin.

arrow

THE ONLY IL-17 INHIBITOR WITH 8-WEEK DOSING1,8-10

View Dosing & Administration

IL=interleukin.

WANT MORE INFORMATION ABOUT BIMZELX?

Get updates and contact a sales representative

IMPORTANT SAFETY INFORMATION

Suicidal Ideation and Behavior

BIMZELX® (bimekizumab-bkzx) may increase the risk of suicidal ideation and behavior (SI/B). A causal association between treatment with BIMZELX and increased risk of SI/B has not been established. Prescribers should weigh the potential risks and benefits before using BIMZELX in patients with a history of severe depression or SI/B. Advise monitoring for the emergence or worsening of depression, suicidal ideation, or other mood changes. If such changes occur, advise to promptly seek medical attention, refer to a mental health professional as appropriate, and re-evaluate the risks and benefits of continuing treatment.

Infections

BIMZELX may increase the risk of infections. Do not initiate treatment with BIMZELX in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing BIMZELX. Instruct patients to seek medical advice if signs or symptoms suggestive of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer BIMZELX until the infection resolves.

Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with BIMZELX. Avoid the use of BIMZELX in patients with active TB infection. Initiate treatment of latent TB prior to administering BIMZELX. Consider anti-TB therapy prior to initiation of BIMZELX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients for signs and symptoms of active TB during and after treatment.

Liver Biochemical Abnormalities

Elevated serum transaminases were reported in clinical trials with BIMZELX. Test liver enzymes, alkaline phosphatase and bilirubin at baseline, periodically during treatment with BIMZELX and according to routine patient management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt BIMZELX until a diagnosis of liver injury is excluded. Permanently discontinue use of BIMZELX in patients with causally associated combined elevations of transaminases and bilirubin. Avoid use of BIMZELX in patients with acute liver disease or cirrhosis.

Inflammatory Bowel Disease

Cases of inflammatory bowel disease (IBD) have been reported in patients treated with IL-17 inhibitors, including BIMZELX. Avoid use of BIMZELX in patients with active IBD. During BIMZELX treatment, monitor patients for signs and symptoms of IBD and discontinue treatment if new onset or worsening of signs and symptoms occurs.

Immunizations

Prior to initiating therapy with BIMZELX, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with BIMZELX.

MOST COMMON ADVERSE REACTIONS

Most common adverse reactions (≥ 1%) are upper respiratory infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, Herpes Simplex infections, acne, folliculitis, other Candida infections, and fatigue.

References:

1. BIMZELX® [prescribing information]. Smyrna, GA: UCB, Inc. 2. Gordon KB, et al. Lancet. 2021;397(10273):475-486. 3. Reich K, et al. N Engl J Med. 2021;385(2):142-152. 4. Reich K, et al. Lancet. 2021;397(10273):487-498. 5. Warren RB, et al. N Engl J Med. 2021;385(2):130-141. 6. Data on file. UCB, Inc.; Smyrna, GA. 7. Strober B, et al. Br J Dermatol. 2023;188(6):749-759. 8. COSENTYX® [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 9. TALTZ® [prescribing information]. Indianapolis, IN: Eli Lilly and Company. 10. SILIQ® [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC.